strong organ growth margin expans continu
even report result miss slightli top-lin upper-
single-digit organ growth profil continu place compani upper-ti larg
cap med-tech bottom-lin compani beat penni rais guidanc
midpoint compar previou outlook think
name continu clean stori posit mako neurotech medsurg
margin expans outweigh revenu miss primarili caus temporari
suppli disrupt trauma extrem solid guidanc year
continu oper margin expans y/i continu believ name
deserv premium valuat current trade in-lin comp thu keep
us construct name
strong result report result slight miss top-lin
organ growth bottom-lin beat penni ep y/i
oper margin expand y/i gm sg leverag regard
segment perform mako robot placement quarter
 bring global instal base shi system knee
franchis continu benefit robot market growth rate
neurotech grew medsurg strong contribut
instrument endoscopi medic primari culprit revenu miss soft
trauma extrem perform fell short consensu estim
due temporari suppli disrupt
guidanc guidanc rais fourth quarter manag
outlook call ep rang includ fx headwind
high point nickel street target full-year
manag guid toward higher end previous provid rang
rais ep rang increas midpoint
compar previou guidanc
point call mani key takeaway call regard
continu mako uptak bolster knee share take posit strong contribut
neurotech medsurg final compani strategi mako instal
base continu expand nearli system instal world-wide
instal competit account report addit
manag report expect gain approv japan china next year
sizeabl market opportun believ syk meaning head start robot
allow preserv knee share take posit despit sever competit
unexpect slowdown surgic volum price pressur
price close octob
ep
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
neurotech busi continu fire cylind broad-bas contribut
neurovascular ischemic/hemorrhag stroke product neuro power tool cmf
compani report expect launch surpass flow divers devic late earli
round portfolio allow captur increment pull-through across neuro
product categori medsurg medic franchis repres largest beat quarter
healthi recoveri busi along solid contribut physio patient
care lastli compani recent activ discuss manag reiter
histor playbook integr captur new market opportun
stock thought share pull back recent week along comp group
howev stock trade multipl in-lin peer continu believ
deserv premium valuat strong market orthoped growth high perform
neuro franchis medsurg consist contribut mention compani abil
deliv steadi oper margin improv anticip leverag go forward
believ investor take advantag soft name tomorrow expect
busi continu deliv solid financi result push level higher
price maintain howev shift multipl
previou pt base ep pt base
ep repres multipl
piper jaffray act financi advisor acquisit piper jaffray
provid histor financi advisori servic hyperbranch medic technolog receiv
invest bank fee close sale
page
page
good gener incom net incom tax net incom analysi gross gener stryker corpor
million except per share data
good sold
percent sale
good sold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
